The Heart Research Institute, Sydney, New South Wales, 2 The University of Sydney, Sydney, New South Wales, 3 Wyss Institute, Harvard, Boston, MA Background: Components of endovascular stents, heart valves and cardiac rhythm devices are made using metal alloys, which are inherently thrombogenic. We have developed a robust, hemocompatible plasma-activated coating (PAC) to covalently bind biomolecules in their bioactive state to metallic surfaces. We then immobilised plasmin, a major mediator of hemostasis, currently used clinically to disrupt clot formation, and investigated its blood compatibility. Methods: PAC was deposited onto stainless steel (SS) substrates in a purpose built plasma polymerization chamber. Blood compatibility was assessed with heparanized whole blood in in vitro assays of clotting under rocking and flow conditions, while cell studies used human coronary artery endothelial cells.
Results: Increasing concentrations of plasmin, 0.1 U, 1.0 U, and 10 U, were covalently immobilized on PAC. Bioactivity was demonstrated using an established enzymatic activity assay, while 10U plasmin coating was also found to support endothelial cell proliferation, increasing 2.6-fold from day 3 to day 5 (p< 0.001). In a whole blood adhesion assay, these surfaces demonstrated a dramatic reduction of thrombus weight in a dose dependant manner, compared to SS controls. PAC alone reduced thrombus weight 45.4AE9.1%, but further reductions were observed for 0.1U (62.3AE6.4%), 1U (78.3AE6.4%) and 10U (90.5AE1.3%) plasmin, relative to SS (p< 0.001). Strikingly, the 10U plasmin surface significantly reduced clot weight 97.7AE1.3% in a modified chandler loop, relative to SS and PAC alone (p< 0.001). Moreover, after freeze-drying and 14 weeks of storage, the reduction of thrombus was persistent (94.6AE8.3%) and not significantly different from freshly prepared surfaces, indicating retention of bioactivity. These findings were successfully translated to a custom laser cut SS stent platform, demonstrating robust PAC adhesion without delamination and similarly striking reductions in thrombus formation. Conclusions: Our PAC technology facilitates the covalent immobilization of plasmin, which dramatically reduced clot formation relative to SS. This has profound potential to improve the efficacy of all metallic vascular implants, and particularly endovascular stents.
TCT-434
Vascular Background: Nitrite is a physiologically important nitric oxide (NO) storage intermediate that is reduced to NO during cardiovascular disease states and serves a cytoprotective function. We evaluated the effects of chronic administration of a novel, sustained release formulation of sodium nitrite (SR-Nitrite, Theravasc, Inc.) on circulating NO levels and coronary vascular function in a clinically relevant model of metabolic syndrome (MetS). Methods: MetS was generated in Ossabaw miniswine fed an atherosclerotic high-fat diet (6 months) resulting in profound coronary vascular dysfunction. SR-Nitrite was administered orally (80 mg/kg b.i.d.) for 3 wks. Plasma levels of nitrite and nitrosothiols (RSNO) were quantified at baseline and following SR-Nitrite. Left anterior descending coronary arteries were isolated, suspended in organ chambers and isometric tension acquired. Following pre-constriction with PGF2a, vascular relaxation to sodium nitroprusside was evaluated. Results: SR-Nitrite therapy increased plasma levels of nitrite (0.35 AE 0.21 vs. 1.2 AE 0.75 mM; p¼0.02) and RSNO (10.7 AE 2.4 vs. 25.4 AE 5.1 nM; p¼0.03) after 3 wks of treatment compared to placebo. SR-Nitrite treatment resulted in significant improvement in vasoreactivity to SNP with maximal relaxation of 39 AE 10% vs. 72 AE 10 %, (p< 0.05).
Conclusions:
In a clinically relevant large animal model of MetS, treatment with SRNitrite increased NO bioavailability and improved ex vivo coronary artery dilation.
TCT-435
Comparison of endothelialization and inflammation between thin-and thickstrut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds in the rabbit iliac artery at 14 and 28 days ). Endothelial cell coverage was assessed using scanning electron microscopy (SEM) and confocal microscopy (CM) following staining for the endothelial marker CD31/PECAM-1 and RAM11-positive monocytes. Results: Endothelial coverage was greatest in Synergy (14days, 27%; 28days, 86%) followed by BioMatrix (14days, 20%; 28days, 65%) and significantly less in Absorb (14 days, 1%; 28 days, 13%) by SEM (14days, P¼0.005; 28days, P¼0.0001, respectively). The percentage of CD31/PECAM-1 positive endothelial cells above struts was similar between BioMatrix (17.3%) and Synergy (13.3%), and significantly less in Absorb (0.5%) (P¼0.023), while RAM11 positive macrophage area was similar between BioMatrix (0.16 mm2) and Synergy (0.17 mm2) and both were significantly less than with Absorb (2.47 mm2) at 28 days (P¼0.0007).
Conclusions: Thin-strut bioerodable polymer everolimus-eluting stents exhibited superiority with respect to re-endothelialization as compared to thick-strut bioerodable polymer biolimus-eluting stents and fully resorbable scaffolds, while monocyte adherence was greatest in the latter. These findings confirm substantial differences in vascular healing among contemporary DES and bioresorbable scaffolds. Background: Previous preclinical experience showed that polymer-coatings of drug eluting stents (DES) lower the predisposition for stent thrombosis compared to bare metal stents. It remains unclear whether relevant differences exist in acute thrombogenicity particularly between current permanent and biodegradable polymers used in clinical practice. Methods: A porcine ex vivo carotid to jugular arteriovenous shunt model involving a test circuit of three in-line stents, was used to test thrombogenicity. The permanent fluoropolymer XIENCE XpeditionÔ everolimus-eluting stent (XIENCE, Abbott Vascular) (n¼24 stents) was compared with 4 CE-marked DES with biodegradable polymer coatings i) BioMatrix FlexÔ (Biosensors) ii) NoboriÒ (Terumo), iii) Orsiro (Biotronik AG), and iv) SynergyÔ (Boston Scientific) (n¼6 each). After 1h of circulation, platelet adherence in whole mount stents was identified by immunofluorescent staining against dual platelet markers (CD61/CD42b) and imaged and quantified under confocal microscopy. Results: XIENCE showed the least area occupied by thrombus compared to the other 4 DES, with a significant difference compared to BioMatrix Flex (p< 0.001) and Synergy (p< 0.001) (Figure) . The number of platelet aggregation clots was also the www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5 :00 PM-7:00 PM JACC Vol 64/11/Suppl B j September 13-17, 2014 j TCT Abstracts/New Devices and Innovation B127
